Andera Partners is to sell its life sciences portfolio company ReViral, to Pfizer for a total consideration of up to USD525 million.
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral therapeutics, with an initial focus on treating respiratory syncytial virus (RSV).
The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals.
Andera co-led ReViral’s Series A funding round of USD21 million in 2015 and re-invested in the subsequent financing rounds alongside a group of international blue chip investors.
